ArticleNature communications2024
Macro CD5L
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
22.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy.Cell genomics · 2025Pooled it
- Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study.Signal transduction and targeted therapy · 2024Trial
- Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma.International journal of molecular sciences · 2026Review
- Neoadjuvant therapy in primary liver cancer: From the missing piece to a new paradigm.Hepatology communications · 2026Article
- Blockage of cuproplasia inhibits pancreatic tumour-associated neutrophils infiltration through TRAF6/STAT3/CCL2 pathway.British journal of cancer · 2026Article
- PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer.Cell death & disease · 2026Article
- Combined administration of interleukin-2 and 18 with anti-PD-L1 antibody induces CCL5-positive CD8 T cells to suppress liver tumors.PNAS nexus · 2026Article
- Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects.Frontiers in immunology · 2026Review
- Stratifying cholangiocarcinoma: tumor microenvironment, molecular drivers, and novel immunotherapeutic approaches.Clinical and molecular hepatology · 2026Review
- FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- PTPN9 dephosphorylates IGF1RJournal of experimental & clinical cancer research : CR · 2025Article
- Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.Cell reports. Medicine · 2025Article
- Single-cell multi-omics in biliary tract cancers: decoding heterogeneity, microenvironment, and treatment strategies.Molecular biomedicine · 2025Review
- Identification of palmitoylation-related lncRNAs as prognostic biomarkers and immune modulators in HCC.Discover oncology · 2025Article
- Establishment of a prognostic model and immune profiling based on phagocytic regulatory genes in hepatocellular carcinoma.Translational cancer research · 2025Article
- APOE deficiency triggers anti-tumour activity of macrophages in liver cancer.Cancer gene therapy · 2025Article
- Omics-driven networks herald a new era of multidimensional therapy for cholangiocarcinoma.Hepatology communications · 2025Article
- CXCL6 Reshapes Lipid Metabolism and Induces Neutrophil Extracellular Trap Formation in Cholangiocarcinoma Progression and Immunotherapy Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Identification of biomarkers associated with exhausted CD8 + T cells in the tumor microenvironment of intrahepatic cholangiocarcinoma based on Mendelian randomization and bioinformatics analysis.Discover oncology · 2025Article
- Mature tertiary lymphoid structures evoke intra-tumoral T and B cell responses via progenitor exhausted CD4Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 5 institutions in 2 countries.
Jia-Cheng Lu *Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID 0000-0001-9557-264X
Lei-Lei Wu *Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, 200031, China.
Yi-Ning Sun *Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, 200031, China.
Xiao-Yong Huang *Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Chao Gao *Liver cancer Institute, Fudan University, Shanghai, 200032, China.
Xiao-Jun GuoDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Hai-Ying ZengDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Xu-Dong QuDepartment of Intervention Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yi ChenLiver cancer Institute, Fudan University, Shanghai, 200032, China.
Dong WuDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yan-Zi PeiDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Xian-Long MengDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yi-Min ZhengDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Chen LiangDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Peng-Fei ZhangKey Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education of the People's Republic of China, Shanghai, 200032, China.
Jia-Bin CaiDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zhen-Bin DingDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Guo-Huan YangDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Ning RenDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Cheng HuangDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Xiao-Ying WangDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Qiang GaoDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Qi-Man SunDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Ying-Hong ShiDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Shuang-Jian QiuDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Ai-Wu KeLiver cancer Institute, Fudan University, Shanghai, 200032, China.
Guo-Ming Shi *Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. shi.guoming@zs-hospital.sh.cn.ORCID 0000-0003-3817-9117
Jian ZhouDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. zhou.jian@zs-hospital.sh.cn.ORCID 0000-0002-2118-1117
Yi-Di SunInstitute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, 200031, China. ydsun@ion.ac.cn.ORCID 0000-0002-4191-2917
Jia FanDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. fan.jia@zs-hospital.sh.cn.ORCID 0000-0001-6386-1068
Sun Yat-sen University · CNMinistry of Education of the People's Republic of China · CNChinese Academy of Sciences · CNFudan University Shanghai Cancer Center · CNFudan University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR profiles of 18 tumor tissues pre- and post- therapy of gemcitabine plus oxaliplatin, in combination with lenvatinib and anti-PD1 antibody for intrahepatic cholangiocarcinoma. We find that high CD8 GZMB
Indexed as
Bile Duct NeoplasmsCholangiocarcinomaPhenylurea CompoundsQuinolinesApoptosis Regulatory ProteinsBile Ducts, IntrahepaticCD8-Positive T-LymphocytesGemcitabineHumansOxaliplatinReceptors, ScavengerApoptosis Regulatory ProteinsCD5L protein, humanGemcitabinelenvatinibOxaliplatinPhenylurea CompoundsQuinolinesReceptors, Scavenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.